Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

Adjacent to the T cells are B cell follicles in which B-2 cells reside (green). Specialized Macrophages in the Marginal Zone There are then two concentric rings of specialized macrophages ...

In addition to their role in the recognition of specific antigen through the BCR, B cells can transport antigen to FDCs, as illustrated by splenic marginal-zone B cells. These cells shuttle from ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

My work focuses on the development of novel therapies for patients with B cell lymphoma, including indolent lymphomas (follicular, marginal zone, small lymphocytic), Waldenström’s macroglobulinemia, ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...